Publication | Open Access

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

Memory T CellsAutoimmune DiseaseDiabetesImmunologyT1dal StudyAutoimmunityDiabetes MellitusNew-onset Type 1Insulin DeliveryImmunotherapyMedicineImmunological Memory